Mobilizing and evaluating anticancer T cells: Pitfalls and solutions

Expert Review of Vaccines

Volumn 12, Issue 11, 2013, Pages 1325-1340

  Robert Tissot, Céline ^a   Nguyen, Linh T ^a   Ohashi, Pamela S ^a,b   Speiser, Daniel E ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

adoptive cell therapy; cancer; correlative studies; immune monitoring; immunotherapy; T cells; vaccine

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 7; INTRINSIC FACTOR; IPILIMUMAB; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; FLOW CYTOMETRY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC MANIPULATION; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LASER CAPTURE MICRODISSECTION; LONG TERM SURVIVAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; PASSIVE IMMUNIZATION; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEOMICS; REGULATORY T LYMPHOCYTE; REVIEW; RNA IMMUNIZATION; RNA SEQUENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84887381126     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.843456     Document Type: Review

References (126)

1. Steinman RM. Decisions about dendritic cells: Past, present, and future. Annu. Rev. Immunol. 30, 1-22 (2012
2. Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu. Rev. Immunol. 17, 829-874 (1999
3. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat. Rev. Immunol. 8(7), 523-532 (2008
4. Sakaguchi S. Multiple Treg suppressive modules and their adaptability. Front. Immunol. 1-6 (2012
5. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T Cells: Mechanisms of Differentiation and Function. Ann. Rev. Immunol. 30(1), 531-564 (2012
6. Almeida JR, Price DA, Papagno L et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204(10), 2473-2485 (2007
7. Darrah PA, Patel DT, De Luca PM et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13(7), 843-850 (2007
8. Baitsch L, Fuertes Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol. 33(7), 364-372 (2012
9. Coulie PG, Van den Eynde BJ, der Bruggen van P, Van Pel A, Boon T. Antigens recognized by T-lymphocytes on human tumours. Biochem. Soc. Trans. 25(2), 544-548 (1997
10. Simpson AJG, Caballero OL, Jungbluth A, Chen Y-T, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5(8), 615-625 (2005
11. Speiser DE, Miranda R, Zakarian A et al. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J. Exp. Med. 186(5), 645-653 (1997
12. Manning J, Indrova M, Lubyova B et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-Associated tumours. Immunology 123(2), 218-227 (2008
13. Garrido F, Cabrera T, Aptsiauri N. Hard and soft lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int. J. Cancer 127(2), 249-256 (2010
14. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med. 209(2), 201-209 (2012
15. Slingluff CL Jr. The present and future of peptide vaccines for cancer. Cancer J. 17(5), 343-350 (2011
16. Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002
17. Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR. A distinct subset of self-renewing human memory CD8+ T Cells survives cytotoxic chemotherapy. Immunity 31(5), 834-844 (2009
18. Nguyen LT, Yen PH, Nie J et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS ONE 5(11), e13940 (2010
19. Butler MO, Friedlander P, Milstein MI et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T Cells. Sci. Transl. Med. 3(80), 80ra34-80ra34 (2011
20. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-Cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011
21. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematol.Am. Soc. Hematol. Educ. Program 675-681 (2009
22. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum. Gene. Ther. 20(11), 1240-1248 (2009
23. Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TNM. Prospects and limitations of T cell receptor gene therapy. Curr. Gene. Ther. 11(4), 276-287 (2011
24. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011
25. Uttenthal BJ, Chua I, Morris EC, Stauss HJ. Challenges in T cell receptor gene therapy. J. Gene. Med. 14(6), 386-399 (2012
26. Gill S, Kalos M. T cell-based gene therapy of cancer. Transl. Res. 161(4), 365-379 (2013
27. Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N. Molecular insights for optimizing T cell receptor specificity against cancer. Front. Immunol. 4, 154 (2013
28. Pellegrini M, Calzascia T, Elford AR et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 15(5), 528-536 (2009
29. Pellegrini M, Mak TW, Ohashi PS. Fighting cancers from within: Augmenting tumor immunity with cytokine therapy. Trends Pharmacol. Sci. 31(8), 356-363 (2010
30. Pardoll DM. Immunology beats cancer: A blueprint for successful translation. Nat. Immunol. 13(12), 1129-1132 (2012
31. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517-2519 (2012
32. Zitvogel L, Kroemer G. Targeting PD-1/ PD-L1 interactions for cancer immunotherapy. OncoImmunology 1(8), 1223-1225 (2012
33. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
34. Paulson KG, Iyer JG, Tegeder AR et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 29(12), 1539-1546 (2011
35. Feldmeyer L, Gaide O, Speiser DE. Clinical implications of CD8+ T-cell infiltration in frequent and rare cancers. J. Investig. Dermatol. 133(8), 1929-1932 (2013
36. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003
37. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY.)313(5795), 1960-1964 (2006
38. Senovilla L, Vacchelli E, Galon J et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology 1(8), 1323-1343 (2012
39. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J. 16(4), 399-403 (2010
40. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012
41. Romano E, Pradervand S, Paillusson A et al. Coexistence of divergent escape mechanisms in a patient with BRAF V600E-mutated cutaneous melanoma treated with vemurafenib. J. Clin. Oncol. 31(Suppl.), Abstract 9014 (2013
42. Hagemann AR, Hagemann IS, Cadungog M et al. Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol. Ther. 12(4), 367-377 (2011
43. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004
44. Speiser DE, Pittet MJ, Rimoldi D et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 13(6), 461-472 (2003
45. Lövgren T, Baumgaertner P, Wieckowski S et al. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol. Immunother. 61(6), 817-826 (2012
46. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 33(4), 451-463 (2010
47. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat. Rev. Immunol. 7(7), 532-542 (2007
48. Fearon DT. The expansion and maintenance of antigen-selected CD8(+) T cell clones. Adv. Immunol. 96, 103-139 (2007
49. Lugli E, Dominguez MH, Gattinoni L et al. Superior T memory stem cell persistence supports long-lived T cell memory. J. Clin. Invest. 123(2), 594-599 (2013
50. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3(5), 431-437 (2003
51. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006
52. Nishimura T, Kaneko S, Kawana-Tachikawa A et al. Generation of Rejuvenated Antigen-Specific T Cells by Reprogramming to Pluripotency and Redifferentiation. Stem Cell 12(1), 114-126 (2013
53. Vizcardo R, Masuda K, Yamada D et al. Regeneration of Human Tumor Antigen-Specific T Cells from iPSCs Derived from Mature CD8+ T Cells. Stem Cell 12(1), 31-36 (2013
54. Speiser DE, Kyburz D, Stübi U, Hengartner H, Zinkernagel RM. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149(3), 972-980 (1992
55. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of highor low-Avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93(9), 4102-4107 (1996
56. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low-And high-Affinity CD8+ T cells in the tumor environment. OncoImmunology 1(8), 1239-1247 (2012
57. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-Affinity antigen. Nature 457(7235), 211-214 (2009
58. Speiser DE. Hit parade for adoptive cell transfer therapy: The best T cells for superior clinical responses. Cancer Discov. 3(4), 379-381 (2013
59. Chinnasamy D, Yu Z, Kerkar SP et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18(6), 1672-1683 (2012
60. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004
61. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012
62. Smits ELJM, Anguille S, Cools N, Berneman ZN, Van Tendeloo VFI. Dendritic cell-based cancer gene therapy. Hum. Gene. Ther. 20(10), 1106-1118 (2009
63. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009
64. Reinis M, Stepanek I, Simova J et al. Induction of protective immunity against MHC class I-deficient, HPV16-Associated tumours with peptide and dendritic cell-based vaccines. Int. J. Oncol. 36(3), 545-551 (2010
65. Pajtasz-Piasecka E, Indrova M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2(2), 257-268 (2010
66. Bonifaz LC. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination. J. Exp. Med. 199(6), 815-824 (2004
67. Speiser DE, Liénard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005
68. Sabbatini PJ, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-Antigen and Poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18(23), 6497-6508 (2012
69. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384 (1991
70. der Bruggen van P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (New York, NY.) 254(5038), 1643-1647 (1991
71. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160(4), 1750-1758 (1998
72. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-Ao0201-binding residues. J. Immunol. 157(6), 2539-2548 (1996
73. Cole DK, Edwards ESJ, Wynn KK et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T Cell recognition. J. Immunol. 185(4), 2600-2610 (2010
74. Ekeruche-Makinde J, Clement M, Cole DK et al. T-Cell Receptor optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J. Biol. Chem. 287(44), 37269-37181 (2012
75. Speiser DE, Baumgaertner P, Voelter V et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl Acad. Sci. USA 105(10), 3849-3854 (2008
76. Gupta B, Iancu EM, Gannon PO et al. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T Cells depends on antigen specificity and differentiation. J. Immunother. 35(6), 488-501 (2012
77. Prehn RT. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J. Natl Cancer Inst. 45(5), 1039-1045 (1970
78. Fotin-Mleczek M, Zanzinger K, Heidenreich R et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene. Med. 14(6), 428-439 (2012
79. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081-1091 (2012
80. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16(1), 3-15 (2006
81. Igney FH, Krammer PH. Death and antideath: Tumour resistance to apoptosis. Nat. Rev. Cancer 2(4), 277-288 (2002
82. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: Tumour-Associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 167(2), 195-205 (2012
83. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 182(8), 4499-4506 (2009
84. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12(4), 253-268 (2012
85. Siegert S, Luther SA. Positive and negative regulation of T cell responses by fibroblastic reticular cells within paracortical regions of lymph nodes. Front. Immunol. 3, 285 (2012
86. Ostman A, Augsten M. Cancer-Associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 19(1), 67-73 (2009
87. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 15, 166-179 (2010
88. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int. J. Cancer 127(4), 759-767 (2010
89. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171), 903-907 (2007
90. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56(5), 739-745 (2007
91. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13(4), 227-242 (2013
92. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol. Rev. 241(1), 104-118 (2011
93. Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4), 409-421 (2004
94. Yang L, Huang J, Ren X et al. Abrogation of TGFb Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis. Cancer Cell 13(1), 23-35 (2008
95. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99(9), 3179-3187 (2002
96. Schwartzentruber DJ, Lawson DH, Richards JM et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364(22), 2119-2127 (2011
97. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
98. Baumgaertner P, Jandus C, Rivals J-P et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer 130, 2607-2617 (2012
99. Taswell C, MacDonald HR, Cerottini JC. Limiting dilution analysis of alloantigen-reactive T lymphocytes. II. Effect of cortisone and cyclophosphamide on cytolytic T lymphocyte precursor frequencies in the thymus. Thymus 1, 119-131 (1979
100. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science (New York, NY.) 274, 94-96 (1996
101. Schmid DA, Irving MB, Posevitz V et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184(9), 4936-4946 (2010
102. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4+ memory-phenotype T Cells are abundant in unexposed adults. Immunity 38(2), 373-383 (2013
103. Bendall SC, Simonds EF, Qiu P et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (New York, NY) 332(6030), 687-696 (2011
104. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T Cell phenotypes. Immunity 36(1), 142-152 (2012
105. Chattopadhyay PK, Roederer M. Cytometry: Todays technology and tomorrows horizons. Methods 57(3), 251-258 (2012
106. Wherry EJ, Ha S-J, Kaech SM et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4), 670-684 (2007
107. Baitsch L, Baumgaertner P, Devêvre E et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121(6), 2350-2360 (2011
108. Wherry EJ. T cell exhaustion. Nat. Immunol. 131(6), 492-499 (2011
109. Bachmann MF, Köhler G, Ecabert B, Mak TW, Kopf M. Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 163(3), 1128-1131 (1999
110. Wing K, Yamaguchi T, Sakaguchi S. Cell-Autonomous and-non-Autonomous roles of CTLA-4 in immune regulation. Drug Discov. Today. 32(9), 428-433 (2011
111. Wang CJ, Kenefeck R, Wardzinski L et al. Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J. Immunol. 189(3), 1118-1122 (2012
112. Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J. Immunol. 189(3), 1123-1127 (2012
113. Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11(12), 852-863 (2011
114. Appay V, Bosio A, Lokan S et al. Sensitive gene expression profiling of human T cell subsets reveals parallel post-Thymic differentiation for CD4+ and CD8+ lineages. J. Immunol. 179(11), 7406-7414 (2007
115. Speiser DE, Wieckowski S, Gupta B et al. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc. Natl Acad. Sci. USA 108(37), 15318-15323 (2011
116. Ma C, Fan R, Ahmad H et al. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat. Med. 17(6), 738-743 (2011
117. Lonchay C, der Bruggen van P, Connerotte T et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14631-14638 (2004
118. Lurquin C, Lethé B, De Plaen E et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med. 201(2), 249-257 (2005
119. Trautmann L, Sekaly R-P. Solving vaccine mysteries: A systems biology perspective. Nat. Immunol. 12(8), 729-731 (2011
120. Taylor CF, Field D, Sansone S-A et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: The MIBBI project. Nat. Biotechnol. 26(8), 889-896 (2008
121. Lee JA, Spidlen J, Boyce K et al. MIFlowCyt: The minimum information about a flow cytometry experiment. Cytometry 73A(10), 926-930 (2008
122. Janetzki S, Britten CM, Kalos M et al. MIATA-minimal information about T cell assays. Immunity 31(4), 527-528 (2009
123. Butterfield LH, Palucka AK, Britten CM et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin. Cancer Res. 17(10), 3064-3076 (2011
124. McShane LM, Altman DG, Sauerbrei W Identification of clinically useful cancer prognostic factors: What are we missing? J. Natl Cancer Inst. 97(14), 1023-1025 (2005
125. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011
126. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12(4), 252-264 (2012